Compare Brookfield Renewable (BEP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Renewable vs Incyte Corporation — how do they compare? Brookfield Renewable trades at $29.83 (market cap $8.95B), while Incyte Corporation trades at $126.49 (market cap $25.40B). The key difference: Incyte Corporation is far larger — about 2.8× Brookfield Renewable's market cap, and Brookfield Renewable pays a 5.26% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BEP | INCY | |
|---|---|---|
Market Cap | $8.95B | $25.40B |
Volume | 2,072,181 | 3,691,836 |
Sector | Utilities | Health |
52-Week High | $37.31 | $129.93 |
52-Week Low | $24.94 | $81.66 |
Enterprise Value | $43.54B | $20.90B |
Dividend Yield | 5.26% | — |
Typical Hold Time | — | 32 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Incyte Corporation (INCY) trades at $125.31, down 1.81% on the day, but maintains a strong fundamental profile with robust profitability margins and a bullish technical outlook. Recent earnings have largely exceeded expectations, with Q2 2026 EPS of $3.09 beating estimates by a wide margin. The company's revenue growth trajectory is solid, projected to reach $5.8 billion in 2026, supported by strong product demand and pipeline progress, as highlighted in recent conference presentations.
The investment outlook for INCY is positive, driven by earnings momentum and analyst consensus favoring a Buy rating with a $130.07 price target. Key opportunities include expanding product portfolios and high gross margins near 93%, while risks involve potential earnings volatility and competitive pressures in the biopharmaceutical sector. The stock's current valuation metrics, including a P/E of 15.96, suggest room for appreciation if growth targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brookfield Renewable
Brookfield Renewable owns and operates renewable power and sustainable solutions businesses. Its portfolio includes hydroelectric, wind, solar, distributed energy, and energy storage assets.
Read more on BEP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
